Xconomy
OCTOBER 12, 2018
Nearly four years after investors snapped up new shares of Juno Therapeutics in a $265 million IPO, cancer immunotherapy remains a hot ticket. Like Juno, Allogene Therapeutics just pulled in a massive IPO haul, nearly $300 million.
Both Sides of the Table
OCTOBER 31, 2015
And actually if you have ADD you may just want to watch the videos I’ve embedded below because it’s easier to concentrate on that than reading a blog post. I can’t write a blog post and then wait 3 days to publish. I study for tests last minute. Of course you should go on your own journey of discovery.
Expert insights. Personalized for you.
74 
Let's personalize your content